Quantification of bone alkaline phosphatase in canine serum

An assay was developed and proven accurate and precise for the quantification of canine serum alkaline phosphatase of bone origin (BAP). The assay uses wheat germ lectin (WGL) which selectively precipitates SAP but not liver alkaline phosphatase (LAP) in serum preincubated for 1 hour at 37 degrees C...

Full description

Saved in:
Bibliographic Details
Published inVeterinary clinical pathology Vol. 22; no. 1; p. 17
Main Authors Sanecki, R.K. (Breathitt Veterinary Center, Hopkinsville, KY), Hoffmann, W.E, Hansen, R, Schaeffer, D.J
Format Journal Article
LanguageEnglish
Published United States 01.03.1993
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:An assay was developed and proven accurate and precise for the quantification of canine serum alkaline phosphatase of bone origin (BAP). The assay uses wheat germ lectin (WGL) which selectively precipitates SAP but not liver alkaline phosphatase (LAP) in serum preincubated for 1 hour at 37 degrees C before conducting the assay. Although a large percentage of corticosteroid-induced alkaline phos- phatase (CAP) is also precipitated by WGL, the activity of this isoenzyme can be determined by utilizing the automated levamisole inhibition assay and BAP determined by subtraction except in those cases in which CAP is very markedly increased. Use of these two assay techniques in combination allows the quantification of LAP, BAP, and CAP activity in canine serum. In sera from adult dogs of various ages, BAP activity represents a mean of 21.27 -/+ 11.4 U/L; however, there was a statistical decrease in BAP activity with age. This allowed the determination of 95% confidence interval for a reference range dependent on age of the dog. Bone AP activity in puppies drops dramatically within the first 3 months, reaching a magnitude of activity consistent with that of the adult dog by approximately 15 months. BAP was increased over adult reference range in five of five dogs tested with osteosarcoma. This assay will now allow conducting a clinical study of the diagnostic significance of bone AP activity in neoplastic and metabolic diseases of bone.
Bibliography:L70
9413562
L50
ISSN:0275-6382
1939-165X
DOI:10.1111/j.1939-165X.1993.tb00871.x